Pulmonary surfactant protein B, deficiency of

Pulmonary Surfactant Protein B Deficiency (SP-B Deficiency) is a rare, genetic, and often fatal lung disorder primarily affecting newborns and infants. It is characterized by a mutation in the Surfactant Protein B (SP-B) gene, leading to a deficiency or absence of the SP-B protein. This protein is crucial for lung function, as it reduces surface tension within the lungs, preventing the collapse of alveoli and facilitating normal respiratory function.

Causes and Genetics

SP-B Deficiency is caused by mutations in the SFTPB gene, which encodes the Surfactant Protein B. This condition is inherited in an autosomal recessive manner, meaning that an individual must inherit two copies of the mutated gene, one from each parent, to be affected. Parents of an individual with an autosomal recessive condition each carry one copy of the mutated gene, but they typically do not show signs and symptoms of the condition.

Symptoms

The primary symptom of SP-B Deficiency is severe respiratory distress shortly after birth. Affected infants may exhibit rapid, labored breathing (tachypnea), grunting, flaring of the nostrils, and cyanosis due to lack of oxygen. Without adequate levels of SP-B, the lungs cannot function properly, leading to difficulty in breathing and inadequate oxygenation of the blood.

Diagnosis

Diagnosis of SP-B Deficiency typically involves a combination of clinical evaluation, imaging studies such as chest X-rays, and genetic testing to identify mutations in the SFTPB gene. Prenatal diagnosis may be possible through genetic testing if there is a known family history of the condition.

Treatment

Treatment options for SP-B Deficiency are limited and primarily supportive. Mechanical ventilation may be required to assist with breathing. In severe cases, lung transplantation may be considered the only viable treatment option. However, the condition is often fatal in early infancy despite aggressive treatment efforts.

Prognosis

The prognosis for infants with SP-B Deficiency is generally poor, with most affected individuals not surviving past infancy. Early and aggressive treatment can improve outcomes in some cases, but the overall survival rate remains low.

Research and Future Directions

Research into SP-B Deficiency is ongoing, with efforts focused on understanding the genetic mechanisms underlying the condition and developing new treatment strategies. Gene therapy and stem cell therapy are areas of interest, offering potential future options for addressing the underlying cause of the disease.

Pulmonary surfactant protein B, deficiency of Resources
Latest articles Most recent articles Ongoing trials	Wikipedia